Recent News

• 12.09.2025 - Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease
• 12.06.2025 - Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting
• 11.24.2025 - Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting

Recent Filings

• 12.08.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.04.2025 - 144 Report of proposed sale of securities
• 12.04.2025 - 144 Report of proposed sale of securities
• 12.03.2025 - 144 Report of proposed sale of securities
• 12.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.01.2025 - 144 Report of proposed sale of securities
• 11.28.2025 - 144 Report of proposed sale of securities
• 11.26.2025 - 144 Report of proposed sale of securities